CBER 101 - Biologics License Application Process

More documents

Recommendations

Info

ACTION Not Ready for Approval • COMPLETE RESPONSE LETTER – Itemizes all deficiencies in the application that must be corrected prior to approval – Stops the review clock • RESUBMISSION – Class 1 or 2 – Restarts the clock C E B R
PDUFA Resubmissions • Guidance for Industry: Classifying Resubmissions in Response to Action Letters, May 14, 1998 • SOPP 8405.1 Procedures for the Classification of Resubmissions of an <strong>Application</strong> for a Product Covered by PDUFA III C E B R
Page 1 and 2: The Biologics License Application P
Page 3 and 4: Drug development phases: Discovery
Page 5 and 6: CBER Regulatory Authority • BIOLO
Page 7 and 8: What is in a BLA? • Form FDA 356h
Page 9 and 10: BLA - Product/Manufacturing Informa
Page 11 and 12: International Harmonization Using t
Page 13 and 14: • MRP Managed Review Process - De
Page 15 and 16: The Review Committee CONSTITUTED TO
Page 17 and 18: Responsibilities Regulatory Project
Page 19 and 20: Before the BLA is Submitted • Pre
Page 21 and 22: SUBMISSION TRACKING NUMBER aaaaaa.b
Page 23 and 24: Refuse To File • A refusal to fil
Page 25 and 26: Complete Review • Substantive rev
Page 27 and 28: Discipline Reviews (DRs) • A DR l
Page 29: Action Decision • After a complet
Page 33 and 34: Dispute Resolution • Guidance for
Page 35 and 36: •SGRA Rules of the Road for Revie
Page 37 and 38: Good Review Management Principles
Page 39 and 40: Good Review Management Principles
Page 41: Good Review Management Principles

CBER 101 - Biologics License Application Process

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?